Cargando…

Ultra-Hypofractionation for Whole-Breast Irradiation in Early Breast Cancer: Interim Analysis of a Prospective Study

We report on the early clinical outcomes of a prospective series of early breast cancer (EBC) patients treated with ultra-hypofractionated post-operative whole-breast irradiation (WBI) after breast-conserving surgery (BCS) and axillary management. Primary endpoints were patient’s compliance and acut...

Descripción completa

Detalles Bibliográficos
Autores principales: Sigaudi, Valeria, Zannetti, Micol, Ferrara, Eleonora, Manfredda, Irene, Mones, Eleonora, Loi, Gianfranco, Krengli, Marco, Franco, Pierfrancesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599048/
https://www.ncbi.nlm.nih.gov/pubmed/36289830
http://dx.doi.org/10.3390/biomedicines10102568
_version_ 1784816499244924928
author Sigaudi, Valeria
Zannetti, Micol
Ferrara, Eleonora
Manfredda, Irene
Mones, Eleonora
Loi, Gianfranco
Krengli, Marco
Franco, Pierfrancesco
author_facet Sigaudi, Valeria
Zannetti, Micol
Ferrara, Eleonora
Manfredda, Irene
Mones, Eleonora
Loi, Gianfranco
Krengli, Marco
Franco, Pierfrancesco
author_sort Sigaudi, Valeria
collection PubMed
description We report on the early clinical outcomes of a prospective series of early breast cancer (EBC) patients treated with ultra-hypofractionated post-operative whole-breast irradiation (WBI) after breast-conserving surgery (BCS) and axillary management. Primary endpoints were patient’s compliance and acute toxicity. Secondary endpoints included physician-rated cosmesis and ipsilateral breast tumour recurrence (IBTR). Acute toxicity was evaluated at the end of WBI, 3 weeks and 6 months thereafter, according to the Common Terminology Criteria for Adverse Events (v. 5.0). Patients were treated between September 2021 and May 2022. The treatment schedule for WBI consisted of either 26 Gy in 5 fractions over one week (standard approach) or 28.5 Gy in 5 fractions over 5 weeks (reserved to elders). Inverse planned intensity-modulated radiation therapy (IMRT) was used employing a static technique. A total of 70 patients were treated. Fifty-nine were treated with the 26 Gy/5 fr/1 w and 11 with the 28.5 Gy/5 fr/5 ws schedule. Median age was 67 and 70 in the two groups. Most of the patients had left-sided tumours (53.2%) in the 26 Gy/5 fr/1 w or right-sided lesions (63.6%) in the 28.5 Gy/5 fr/5 ws group. Most of the patients had a clinical T1N0 disease and a pathological pT1pN0(sn) after surgery. Ductal invasive carcinoma was the most frequent histology. Luminal A intrinsic subtyping was most frequent. Most of the patients underwent BCS and sentinel lymph node biopsy and adjuvant endocrine therapy. All patients completed the treatment program as planned. Maximum detected acute skin toxicities were grade 2 erythema (6.7%), grade 2 induration (4.4%), and grade 2 skin colour changes. No early IBTR was observed. Ultra-hypofractionated WBI provides favourable compliance and early clinical outcomes in EBC after BCS in a real-world setting.
format Online
Article
Text
id pubmed-9599048
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95990482022-10-27 Ultra-Hypofractionation for Whole-Breast Irradiation in Early Breast Cancer: Interim Analysis of a Prospective Study Sigaudi, Valeria Zannetti, Micol Ferrara, Eleonora Manfredda, Irene Mones, Eleonora Loi, Gianfranco Krengli, Marco Franco, Pierfrancesco Biomedicines Article We report on the early clinical outcomes of a prospective series of early breast cancer (EBC) patients treated with ultra-hypofractionated post-operative whole-breast irradiation (WBI) after breast-conserving surgery (BCS) and axillary management. Primary endpoints were patient’s compliance and acute toxicity. Secondary endpoints included physician-rated cosmesis and ipsilateral breast tumour recurrence (IBTR). Acute toxicity was evaluated at the end of WBI, 3 weeks and 6 months thereafter, according to the Common Terminology Criteria for Adverse Events (v. 5.0). Patients were treated between September 2021 and May 2022. The treatment schedule for WBI consisted of either 26 Gy in 5 fractions over one week (standard approach) or 28.5 Gy in 5 fractions over 5 weeks (reserved to elders). Inverse planned intensity-modulated radiation therapy (IMRT) was used employing a static technique. A total of 70 patients were treated. Fifty-nine were treated with the 26 Gy/5 fr/1 w and 11 with the 28.5 Gy/5 fr/5 ws schedule. Median age was 67 and 70 in the two groups. Most of the patients had left-sided tumours (53.2%) in the 26 Gy/5 fr/1 w or right-sided lesions (63.6%) in the 28.5 Gy/5 fr/5 ws group. Most of the patients had a clinical T1N0 disease and a pathological pT1pN0(sn) after surgery. Ductal invasive carcinoma was the most frequent histology. Luminal A intrinsic subtyping was most frequent. Most of the patients underwent BCS and sentinel lymph node biopsy and adjuvant endocrine therapy. All patients completed the treatment program as planned. Maximum detected acute skin toxicities were grade 2 erythema (6.7%), grade 2 induration (4.4%), and grade 2 skin colour changes. No early IBTR was observed. Ultra-hypofractionated WBI provides favourable compliance and early clinical outcomes in EBC after BCS in a real-world setting. MDPI 2022-10-13 /pmc/articles/PMC9599048/ /pubmed/36289830 http://dx.doi.org/10.3390/biomedicines10102568 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sigaudi, Valeria
Zannetti, Micol
Ferrara, Eleonora
Manfredda, Irene
Mones, Eleonora
Loi, Gianfranco
Krengli, Marco
Franco, Pierfrancesco
Ultra-Hypofractionation for Whole-Breast Irradiation in Early Breast Cancer: Interim Analysis of a Prospective Study
title Ultra-Hypofractionation for Whole-Breast Irradiation in Early Breast Cancer: Interim Analysis of a Prospective Study
title_full Ultra-Hypofractionation for Whole-Breast Irradiation in Early Breast Cancer: Interim Analysis of a Prospective Study
title_fullStr Ultra-Hypofractionation for Whole-Breast Irradiation in Early Breast Cancer: Interim Analysis of a Prospective Study
title_full_unstemmed Ultra-Hypofractionation for Whole-Breast Irradiation in Early Breast Cancer: Interim Analysis of a Prospective Study
title_short Ultra-Hypofractionation for Whole-Breast Irradiation in Early Breast Cancer: Interim Analysis of a Prospective Study
title_sort ultra-hypofractionation for whole-breast irradiation in early breast cancer: interim analysis of a prospective study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599048/
https://www.ncbi.nlm.nih.gov/pubmed/36289830
http://dx.doi.org/10.3390/biomedicines10102568
work_keys_str_mv AT sigaudivaleria ultrahypofractionationforwholebreastirradiationinearlybreastcancerinterimanalysisofaprospectivestudy
AT zannettimicol ultrahypofractionationforwholebreastirradiationinearlybreastcancerinterimanalysisofaprospectivestudy
AT ferraraeleonora ultrahypofractionationforwholebreastirradiationinearlybreastcancerinterimanalysisofaprospectivestudy
AT manfreddairene ultrahypofractionationforwholebreastirradiationinearlybreastcancerinterimanalysisofaprospectivestudy
AT moneseleonora ultrahypofractionationforwholebreastirradiationinearlybreastcancerinterimanalysisofaprospectivestudy
AT loigianfranco ultrahypofractionationforwholebreastirradiationinearlybreastcancerinterimanalysisofaprospectivestudy
AT krenglimarco ultrahypofractionationforwholebreastirradiationinearlybreastcancerinterimanalysisofaprospectivestudy
AT francopierfrancesco ultrahypofractionationforwholebreastirradiationinearlybreastcancerinterimanalysisofaprospectivestudy